Supplemental Figure 1: Sensitivity Analysis of Efficacy of Solriamfetol in Participants With or Without a History of Depression[a]

(A) Mean Sleep Latency on Maintenance of Wakefulness Test



(B) Epworth Sleepiness Scale Scores



(C) Improvement on Patient Global Impression of Change[b]



[a]Excluding participants without a history of depression who were using concomitant antidepressants. [b]Improvement defined as *minimally, much,* or *very much improved*. **P*<0.05 vs placebo. ***P*<0.01 vs placebo. ****P*<0.0001 vs placebo. *P* values are nominal. Note: Higher mean sleep latency on the MWT indicates greater ability to stay awake and less severe EDS, whereas higher scores on the ESS represent more severe EDS (Johns, 1991; Littner et al., 2005). ESS, Epworth Sleepiness Scale; LS, least squares; MWT, Maintenance of Wakefulness Test; n/a, not applicable; OSA, obstructive sleep apnea; PGI-C, Patient Global Impression of Change; SE, standard error.

Supplemental Table 1. Terms Used to Identify History of Depression in Medical History at Screening

	Narcolepsy		OSA	
Preferred Term, *n* (%)	**Placebo (*N*=59)**	**Combined Solriamfetol (*N*=177)**	**Placebo (*N*=119)**	**Combined Solriamfetol (*N*=355)**
Affective disorder	0	1 (1)	0	0
Depression	17 (29)	44 (25)	22 (19)	82 (23)
Depressed mood	0	0	1 (1)	0
Major depression	0	1 (1)	1 (1)	3 (1)
Postpartum depression	0	3 (2)	1 (1)	0
Seasonal affective disorder	0	0	1 (1)	0

OSA, obstructive sleep apnea.

Supplemental Table 2. Sensitivity Analysis of Rates of Common TEAEs in Participants With or Without a History of Depression[a,b]

	Narcolepsy				OSA			
	History of Depression		No History of Depression		History of Depression		No History of Depression	
Preferred Term, *n* (%)	**Placebo (*N*=17)**	**Combined Solriamfetol (*N*=48)**	**Placebo (*N*=39)**	**Combined Solriamfetol (*N*=125)**	**Placebo (*N*=26)**	**Combined Solriamfetol (*N*=85)**	**Placebo (*N*=90)**	**Combined Solriamfetol (*N*=250)**
Any TEAE	10 (59)	40 (83)	15 (39)	79 (63)	11 (42)	57 (67)	44 (49)	171 (68)
Headache	2 (12)	11 (23)	1 (3)	26 (21)	2 (8)	4 (5)	7 (8)	29 (12)
Decreased appetite	1 (6)	8 (17)	0	11 (9)	0	5 (6)	1 (1)	21 (8)
Nausea	1 (6)	7 (15)	0	12 (10)	0	7 (8)	7 (8)	19 (8)
Anxiety	0	5 (10)	1 (3)	3 (2)	0	8 (9)	0	16 (6)
Insomnia	0	4 (8)	0	1 (1)	0	2 (2)	1 (1)	12 (5)
Upper respiratory tract infection	1 (6)	4 (8)	0	1 (1)	0	3 (4)	3 (3)	0
Dry mouth	0	3 (6)	2 (5)	10 (8)	0	7 (8)	2 (2)	9 (4)
Fatigue	0	3 (6)	0	2 (2)	1 (4)	0	1 (1)	4 (2)
Nasopharyngitis	2 (12)	5 (10)	1 (2.6)	11 (9)	2 (8)	3 (4)	6 (7)	14 (6)

[a]Excluding participants without a history of depression who were using concomitant antidepressants. [b]Common TEAEs are those with incidence ≥5% in ≥1 solriamfetol-treated subgroup. OSA, obstructive sleep apnea; TEAE, treatment-emergent adverse event.